Medistim ASA (0OCD) Q2 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Medistim Asa.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.340 Good morning everyone and welcome to the second quarter and first half 2025 00:00:05.340 -- 00:00:09.528 financial results presentations from Medistim. 00:00:09.528 -- 00:00:14.957 My name is Kari Krogstad and as usual I'm joined by my good colleague 00:00:14.957 -- 00:00:20.724 CFO Thomas Jakobsen and together we will take you through the results. 00:00:21.665 -- 00:00:27.252 And just before we dive into the highlights, 00:00:27.252 -- 00:00:32.498 we like to start by reminding everyone of our track record. 00:00:32.498 -- 00:00:37.505 This is a great reminder of our goal and ambition, which has been and still is to 00:00:37.505 -- 00:00:42.191 deliver profitable and growth consistently over time. 00:00:42.191 -- 00:00:46.696 So we can see quarter variations, but our track record shows that we have succeeded to 00:00:46.696 -- 00:00:50.369 deliver on this promise over the years. 00:00:50.369 -- 00:00:55.695 But now let's look at the second quarter and the second quarter highlights. 00:00:55.739 -- 00:01:00.909 So I'm very happy and proud to be able to present the second best quarter, 00:01:00.909 -- 00:01:06.907 both for sales and EBIT, and it's actually only beaten by the first quarter this year. 00:01:06.907 -- 00:01:13.216 So we're seeing revenue performance at 169.1 million NOX, 00:01:13.216 -- 00:01:15.696 which is 16.7% 00:01:15.779 -- 00:01:21.026 growth over the same quarter last year. And as this slide shows, 00:01:21.026 -- 00:01:23.930 there is only a slight currency effect here. 00:01:23.930 -- 00:01:30.697 So if we look at the currency neutral sales development, the total sales is up 15.7%. 00:01:31.848 -- 00:01:36.853 And as always, we are extremely satisfied to see that it's our 00:01:36.853 -- 00:01:41.738 own prod...